Oral Dydrogesterone for LPS in Women Undergoing FET.
Higher patient satisfaction, fewer side effects and non-inferiority in clinical outcomes make oral dydrogesterone a better option than vaginal & injectable progesterone.
DIVATRONE
Indian experts conducted a systematic review and meta-analysis of 366 randomized controlled trials (RCTs) between 1970 and October 2022 to assess the effectiveness of oral dydrogesterone, vaginal progesterone, and intramuscular progesterone for luteal-phase support (LPS) in women undergoing frozen embryo transfer (FET).
Thirty full-text publications were chosen from a total of 366 research, and eight of those articles were used in this FET meta-analysis.
There was no significant difference observed in clinical pregnancy, live births, or miscarriages between the dydrogesterone, vaginal progesterone, and intramuscular progesterone groups.
Patient satisfaction levels were considerably higher among women on oral dydrogesteroneas compared to those on vaginal progesterone.
Similarly, among those who got dydrogesterone, women were the least likely to experience at least one side effect.